Biotech News
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
ir.syndax.com2026-05-06 14:52 EST
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim